Cargando…

Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts

BACKGROUND: The Notch ligand Delta-like 4 (Dll4) is highly expressed in vascular endothelium and has been shown to play a pivotal role in regulating tumor angiogenesis. Blockade of the Dll4-Notch pathway in preclinical cancer models has been associated with non-productive angiogenesis and reduced tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miles, Kiersten Marie, Seshadri, Mukund, Ciamporcero, Eric, Adelaiye, Remi, Gillard, Bryan, Sotomayor, Paula, Attwood, Kristopher, Shen, Li, Conroy, Dylan, Kuhnert, Frank, Lalani, Alshad S., Thurston, Gavin, Pili, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231048/ https://www.ncbi.nlm.nih.gov/pubmed/25393540 http://dx.doi.org/10.1371/journal.pone.0112371

Ejemplares similares

Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer
por: Fontana, Luigi, et al.
Publicado: (2013)

Dll4-Notch signaling as a therapeutic target in tumor angiogenesis
por: Kuhnert, Frank, et al.
Publicado: (2011)

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
por: Ciamporcero, Eric, et al.
Publicado: (2015)

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma
por: Ramakrishnan, Swathi, et al.
Publicado: (2016)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
por: Pili, Roberto, et al.
Publicado: (2017)

ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
por: Yeom, Dong-Hoon, et al.
Publicado: (2020)

Dll4-Notch Signalling Blockade Synergizes Combined Ultrasound-Stimulated Microbubble and Radiation Therapy in Human Colon Cancer Xenografts
por: El Kaffas, Ahmed, et al.
Publicado: (2014)

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression
por: Ellis, Leigh, et al.
Publicado: (2011)

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts
por: Wei, Lei, et al.
Publicado: (2016)

Dll4 Blockade Promotes Angiogenesis in Nonhealing Wounds of Sox7-Deficient Mice
por: Yang, Jee Myung, et al.
Publicado: (2020)

Association of Dll4/Notch and HIF-1a -VEGF Signaling in the Angiogenesis of Missed Abortion
por: Fang, Yan, et al.
Publicado: (2013)

Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade
por: Singh, Rohit, et al.
Publicado: (2013)

Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis
por: Vincent-Chong, Vui King, et al.
Publicado: (2019)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

Dll4 blockade interferes with the bone marrow vascular niche and perturbs hematopoietic recovery following myeloablation
por: Remédio, Leonor, et al.
Publicado: (2010)

Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
por: Geffers, Insa, et al.
Publicado: (2007)

Context-Dependent Functional Divergence of the Notch Ligands DLL1 and DLL4 In Vivo
por: Preuße, Kristina, et al.
Publicado: (2015)

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
por: Kim, Da-Hyun, et al.
Publicado: (2020)

Influence of Dll4 via HIF-1α-VEGF Signaling on the Angiogenesis of Choroidal Neovascularization under Hypoxic Conditions
por: Dong, Xiao, et al.
Publicado: (2011)

Preliminary Research of Main Components of Dll4/ Notch-VEGF Signaling Pathway Under High-Glucose Stimulation in vitro
por: Gao, Na, et al.
Publicado: (2022)

Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine
por: Shimizu, Hiromichi, et al.
Publicado: (2014)

VEGF blockade damages brain vessels
por: Bashyam, Hema
Publicado: (2008)

Anti-angiogenic alternatives to VEGF blockade
por: Khan, Kabir A., et al.
Publicado: (2015)

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
por: Shen, Li, et al.
Publicado: (2012)

The Angiogenic Secretome in VEGF overexpressing Breast Cancer Xenografts
por: Dore-Savard, Louis, et al.
Publicado: (2016)

Foxc Transcription Factors Directly Regulate Dll4 and Hey2 Expression by Interacting with the VEGF-Notch Signaling Pathways in Endothelial Cells
por: Hayashi, Hisaki, et al.
Publicado: (2008)

Altered ratios of pro‐ and anti‐angiogenic VEGF‐A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma
por: Ye, Xi, et al.
Publicado: (2016)

Polychlorinated biphenyls target Notch/Dll and VEGF R2 in the mouse placenta and human trophoblast cell lines for their anti-angiogenic effects
por: Kalkunte, Satyan, et al.
Publicado: (2017)

Xuan Bi Tong Yu Fang Promotes Angiogenesis via VEGF-Notch1/Dll4 Pathway in Myocardial Ischemic Rats
por: Li, Shuangdi, et al.
Publicado: (2020)

Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response
por: Folaron, Margaret, et al.
Publicado: (2019)

Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses
por: Srivastava, Minu, et al.
Publicado: (2015)

Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
por: Jubb, A M, et al.
Publicado: (2009)

The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis
por: FRANCESCUTTI, VALERIE, et al.
Publicado: (2013)

Normal Development in Mice Over-Expressing the Intracellular Domain of DLL1 Argues against Reverse Signaling by DLL1 In Vivo
por: Redeker, Christian, et al.
Publicado: (2013)

The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro
por: Tveriakhina, Lena, et al.
Publicado: (2018)

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer
por: Kalmuk, James, et al.
Publicado: (2015)

Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models
por: Eichten, Alexandra, et al.
Publicado: (2012)

Equine ovarian tissue xenografting: impacts of cooling, vitrification, and VEGF
por: Souza, Samara Silva, et al.
Publicado: (2021)

Clinical implications of DLL4 expression in gastric cancer
por: Ishigami, Sumiya, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4euahdie9f5i0a2ubqqqd4puiv